P107-Ab0089
Harvesting Convalescent Plasma for Hyperimmune Intravenous Globulin Production: A Multicentre, Randomised Double-Blind Controlled Trial for Treatment of Patients with Serious S-OIV H1N1 Infection

1Carol Yu Centre for Infection and Division of Infectious Diseases, Queen Mary Hospital, State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong, 2Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, 3Hong Kong Red Cross Blood Transfusion Service, Hong Kong, 4Department of Intensive Care Unit, United Christian Hospital, Hong Kong, 5Department of Intensive Care Unit, Pamela Youde Nethersole Eastern Hospital, Hong Kong, 6Department of Anaesthesia and Intensive Care Unit, Queen Mary Hospital, Hong Kong, 7Department of Medicine and Geriatrics, Intensive Care Unit, Caritas Medical Centre, Hong Kong, 8Department of Medicine, Ruttonjee Hospital and Tang Shiu Kin Hospitals, Hong Kong, 9Department of Intensive Care Medicine, Queen Elizabeth Hospital, Hong Kong, 10Department of Infection, Emergency & Contingency, Hospital Authority, Hong Kong

Background: Experience from influenza pandemics suggested that convalescent plasma treatment given within 4 to 5 days of symptom onset might be beneficial. However, robust treatment data is lacking.

Methods: This is a multicentre prospective double-blind randomized controlled trial. Convalescent plasma from patients who recovered from the 2009 pandemic influenza [A(H1N1)pdm09] infection was fractionated to hyperimmune intravenous immunoglobulin (H-IVIG) by CSL Bioplasma, Australia. Patients with severe A(H1N1)pdm09 infection on standard antiviral treatment requiring intensive care and ventilatory support were randomized to receive H-IVIG or normal IVIG manufactured before 2009 as control. Clinical outcome and adverse effects were compared.

Results: Between 2010 and 2011, thirty-five patients were randomized to receive H-IVIG (17 patients) or IVIG (18 patients). One defaulted patient was excluded from analysis. No adverse event related to treatment was reported. Baseline demographics and viral load before treatment were similar between the two groups. Serial respiratory viral load demonstrated that H-IVIG treatment was associated with significantly lower day 5 and 7 post-treatment viral load compared to the control (p=0.04 and p=0.02 respectively). The initial serum cytokine level was significantly higher in the H-IVIG group but fell to similar level 3 days after treatment. Subgroup multivariate analysis of the 22 patients who received treatment within 5 days of symptom onset demonstrated that H-IVIG treatment was the only factor which independently reduced mortality [OR:0.14, 95% CI, 0.02-0.92; p=0.04].

Conclusions: Treatment of severe A(H1N1)pdm09 infection with H-IVIG within 5 days of symptom onset was associated with a lower viral load and reduced mortality.

Ref. No.: CS-7

P108-Ab0090
In Silico Structure-based Screening and Characterization of Inhibitors for Influenza A Virus Nucleoprotein

Chun-Yeung Lo1, Ming Liu1, Li-Min Poon2, Pang-Chui Shaw1
1Centre for Protein Science and Crystallography, School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, 2Centre of Influenza Research and School of Public Health, The University of Hong Kong, Hong Kong

The trend of drug resistance developed in different strains of influenza viruses is worrying, and it is of utmost importance and urgency to develop new drugs against this virus. The viral nucleoprotein (NP) is a major component of the ribonucleoprotein (RNP) complex for the transcription and replication of the virus. In order to maintain a stable RNP structure, NP forms homooligomers by inserting its tail-loop to the tail-loop insertion site of another NP. In this study, we have employed structure-based virtual screening on the influenza A NP tail loop insertion site and found two hit compounds number 7 and 16 that can subdue influenza RNP activities. Subsequently, two analogs from compound 16 were identified which inhibit RNP activities of various influenza A subtypes and viral growth at micromolar levels. These analogs were also shown to directly interact with NP at 12.0 ± 1.25 and 41.6 ± 1.93 μM respectively by surface plasmon resonance assay. These novel anti-influenza compounds would provide a template for designing drug candidates with higher potency.

Ref. No.: 10090022

P109-Ab0091
A Detailed Longitudinal Study of Infection Attack Rates among Healthy Adults in Hong Kong during the Epidemiic of the Human Swine Influenza A/H1N1 Virus in 2009

Joseph Wu1, Andrew Ho1, Edward Ma1, Cheuk Kwong Lee1, Daniel Chu1, Po Lai Ho1, Ivan Hung1, Lai Ming Ho1, Che Kit Lin2, Thomas Tsang3, Si Vu Lo1, Yu Lung Lau1, Gabriel Leung1, Benjamin Cowling1, Malik Peiris1
1The University of Hong Kong, Hong Kong, 2Red Cross Blood Transfusion Services, Hong Kong, 3Centre for Health Protection, Hong Kong, Hong Kong, 4Hospital Authority, Hong Kong

Background: In an emerging influenza pandemic, estimating severity (the probability of a severe outcome, such as hospitalization, if infected) is a public health priority. As many influenza infections are subclinical, sero-surveillance is needed to allow reliable real-time estimates of infection attack rate (IAR) and severity.

Methods and Results: We tested 14,766 sera collected during the first wave of the 2009 pandemic in Hong Kong using viral microneutralization. We estimated IAR and infection-hospitalization probability (IHP) from the serial cross-sectional serologic data and hospitalization data. Had our serologic data been available weekly in real time, we would have obtained reliable IHP estimates 1 wk after, 1-2 wk before, and 3 wk after epidemic peak for individuals aged 5-14 y, 15-29 y, and 30-59 y. The ratio of IAR to pre-existing seroprevalence, which decreased with age, was a major determinant for the timeliness of reliable estimates. If we began sero-surveillance 3 wk after community transmission was confirmed, with 150, 350, and 500 specimens per week for individuals aged 5-14 y, 15-19 y, and 20-29 y, respectively, we would have obtained reliable IHP estimates for these age groups 4 wk before the peak. For 30-59 y olds, even 800 specimens per week would not have generated reliable estimates until the peak because the ratio of IAR to pre-existing.